# Study of Diagnostic Performance of [18F]CTT1057 for PSMA-positive Tumors Detection

> **NCT04838626** · PHASE2,PHASE3 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 195 (actual)

## Conditions studied

- Prostatic Neoplasms
- Prostate Cancer

## Interventions

- **DRUG:** [18F]CTT1057

## Key facts

- **NCT ID:** NCT04838626
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-09-07
- **Primary completion:** 2023-11-24
- **Final completion:** 2023-11-24
- **Target enrollment:** 195 (ACTUAL)
- **Last updated:** 2025-10-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04838626

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04838626, "Study of Diagnostic Performance of [18F]CTT1057 for PSMA-positive Tumors Detection". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT04838626. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*